Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADGN-122
- Development stage
- Preclinical
- Lead developer
- Aanastra
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
ADGN-122 is a gene-editing therapeutic candidate designed to target the KRAS G12V mutation, a specific oncogenic variant of the KRAS gene frequently found in several cancers. The drug utilizes proprietary single-guide RNA (sgRNA) technology complexed with mRNA Cas9 for targeted in vivo delivery and editing of the mutant KRAS gene. Its mechanism involves inhibiting or editing the GTPase activity of KRAS G12V, thereby disrupting downstream signaling pathways that drive tumor growth and survival. ADGN-122 is being developed primarily for oncology indications, including colorectal cancer, lung cancer, and pancreatic cancer. The developer is Aanastra Inc., which collaborates closely with Divincell SAS on RNA therapeutics platforms[1][3][4].
02
Targets
KRASG12V (KRAS G12V)
Beyond the preview
Go deeper on ADGN-122.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADGN-122.